Form 4 for AKTS Aktis Oncology, Inc.
Accepted 2026-07-21 20:50:28 ET · period of report 2026-07-20 · accession 0001193125-26-310991 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2026-07-21 20:50 | 2026-07-20 | AKTS | Herrmann Ken | Dir | M - OptEx | $0.5888 | +4,856 | 4,856 | New | +$2,859 |
| DM | 2026-07-21 20:50 | 2026-07-20 | AKTS | Herrmann Ken | Dir | S - Sale+OE | $24.56 | -4,856 | 0 | -100% | -$119.3K |
| DM | 2026-07-21 20:50 | 2026-07-20 | AKTS | Herrmann Ken | Dir | M - OptEx | $0.00 | -4,856 | 18.4K | -21% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-07-20 | M | A | 3,506 | $0.08 | 3,506 | D | — | — | |
| 2 | Common | Common Stock | 2026-07-20 | M | A | 1,350 | $1.91 | 4,856 | D | — | — | |
| 3 | Common | Common Stock | 2026-07-20 | S | D | 3,506 | $24.56 | 1,350 | D | — | — | (F1) The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.50 to $24.66, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. |
| 4 | Common | Common Stock | 2026-07-20 | S | D | 1,350 | $24.56 | 0 | D | — | — | (F1) The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.50 to $24.66, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. |
| 5 | Derivative | Stock Option (Right to Buy) | 2026-07-20 | M | D | 3,506 | $0.00 | 0 | D | $0.08 · — to 2030-11-23 | 3,506 Common Stock | (F2) These options have vested in full. |
| 6 | Derivative | Stock Option (Right to Buy) | 2026-07-20 | M | D | 1,350 | $0.00 | 18,364 | D | $1.91 · — to 2031-04-14 | 1,350 Common Stock | (F2) These options have vested in full. |